Kamada (KMDA) Rating Lowered to Sell at ValuEngine
ValuEngine lowered shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research report sent to investors on Thursday.
KMDA has been the topic of a number of other reports. Zacks Investment Research downgraded Kamada from a hold rating to a strong sell rating in a research report on Thursday, November 16th. Chardan Capital started coverage on Kamada in a research note on Friday, February 2nd. They set a buy rating and a $7.00 target price on the stock. HC Wainwright reaffirmed a buy rating on shares of Kamada in a research note on Thursday, February 8th. Finally, TheStreet raised Kamada from a c rating to a b rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Kamada has a consensus rating of Hold and a consensus price target of $7.00.
Shares of Kamada (NASDAQ:KMDA) opened at $5.25 on Thursday. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.30. The stock has a market capitalization of $211.38, a P/E ratio of 30.88 and a beta of 1.12.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after buying an additional 28,382 shares during the last quarter. Analyst IMS Investment Management Services Ltd. grew its stake in shares of Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after buying an additional 50,000 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Kamada during the third quarter valued at approximately $112,000. ARK Investment Management LLC bought a new position in shares of Kamada during the fourth quarter valued at approximately $251,000. Finally, Worth Venture Partners LLC bought a new position in shares of Kamada during the third quarter valued at approximately $246,000. 9.05% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Kamada (KMDA) Rating Lowered to Sell at ValuEngine” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/kamada-kmda-rating-lowered-to-sell-at-valuengine/1909037.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.